Edwards Lifesciences (NYSE:EW) Given Buy Rating at BTIG Research

Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued to clients and investors on Friday, September 11th, Benzinga reports. They currently have a $110.00 price target on the medical research company’s stock. BTIG Research’s target price would suggest a potential upside of 24.65% from the stock’s previous close.

EW has been the subject of a number of other reports. Piper Sandler reissued an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. TD Cowen restated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Evercore reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Finally, Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.77.

Edwards Lifesciences Stock Performance

EW traded down $0.04 during trading on Friday, hitting $88.25. The stock had a trading volume of 1,481,964 shares, compared to its average volume of 4,468,891. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a market capitalization of $50.81 billion, a P/E ratio of 50.76, a PEG ratio of 2.29 and a beta of 0.87. The company’s 50-day moving average price is $88.24 and its 200 day moving average price is $86.48. Edwards Lifesciences has a twelve month low of $74.66 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts forecast that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,045 shares of company stock valued at $451,596 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rehmann Capital Advisory Group raised its position in Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares during the last quarter. Stephens Inc. AR grew its position in shares of Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after purchasing an additional 144 shares during the last quarter. Aspen Investment Management Inc grew its position in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company’s stock valued at $885,000 after purchasing an additional 150 shares during the last quarter. NorthRock Partners LLC grew its position in shares of Edwards Lifesciences by 1.0% in the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after purchasing an additional 153 shares during the last quarter. Finally, Elevation Wealth Partners LLC increased its stake in shares of Edwards Lifesciences by 24.8% during the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock worth $67,000 after purchasing an additional 155 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.